Biomedical Reports Special Issues

STUDY OF THE INTERRELATIONSHIP ANGIOGENESIS-INFLAMMATION-OXIDATIVE STRESS IN PATIENTS DIAGNOSED WITH INFLAMMATORY BOWEL DISEASES

Lead Editor:

    Professor BOLDEANU MIHAIL VIRGIL
    University of Medicine and Pharmacy of Craiova
    Romania

Although the research of the last decades led to the discovery of biological therapy with human monoclonal antibodies, which allowed a better regulation of the activity of the cellular immune response and the inflammation of the intestinal mucosa, with clinical remission and endoscopic healing, there are patients in whom mucosal healing is not observed or altering the natural history of inflammatory bowel disease. Starting from these observations, we propose in this special issue to collect important studies, both preliminary ones, regarding the evaluation of angiogenic, inflammatory status, and oxidative stress in patients with IBD. Studies investigating the hypothesis that angiogenesis and oxidative stress contribute significantly to mucosal inflammation in IBD are also welcome. Studying the interrelation between angiogenic factors - inflammatory markers - oxidative stress factors can lead to an objective measurement of disease activity, because symptoms are often subjective, and invasive procedures are often a burden for the patient.


Submission deadline: 10 July 2024

Confronting the unmet therapeutic needs in major depressive disorder- New antidepressants in clinical practice and promises from the pipeline

Lead Editor:

    Dr Octavian Vasiliu
    Dr. Carol Davila University Emergency Central Military Hospital
    Romania

Although depressive disorders benefit from a large variety of therapeutic agents launched in clinical practice in the last six decades, the rates of non-responsiveness and partial response are still high. A new wave of antidepressants has been approved in the last 5 years by various national or regional agencies with responsibilities in the field of medicines authorization, for depressive disorders (major depressive disorder, postpartum depression, and treatment-resistant depression)- gepirone, esketamine, toludesvenlafaxine, zuranolone, brexanolone, and the combination dextromethorphan+bupropion. The available, limited data, support the efficacy and safety of these new pharmacological agents, but extensive research is needed in order to evaluate their long-term clinical effects. Other investigational products with anti-depressive properties are explored in preclinical studies and clinical trials, such as monoaminergic agents, orexin receptor antagonists, anti-cytokines, sestrin modulators, glutamatergic agents, cholinergic receptor modulators, etc. Original studies, case series, reviews, and meta-analyses focused on exploring such agents are expected to enrich the current knowledge on this topic with important clinical consequences.


Submission deadline: 13 May 2024

The genetics of neurodegenerative disorders

Lead Editor:

    Dr Safia Messaoudi
    Naif arab university for Security Sciences
    Saudi Arabia

Neurodegenerative disorders are a group of conditions characterized by the progressive degeneration of the structure and function of the nervous system. Some well-known neurodegenerative disorders include Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). These conditions often result in the gradual loss of cognitive and motor functions and can have a significant impact on a person's quality of life. It's important to note that these disorders have complex genetic components that play a significant role in their pathogenesis and therefore the detection of genetic biomarkers can be crucial for their diagnosis, prognosis, and treatment to be a focus for early detection and personalized treatment.


Submission deadline: 12 April 2024

Cancer Metabolism in Tumor Immunology

Lead Editor:

    Dr Xuelei Ma
    State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy
    China

In recent years, the links between oncogenes, tumour suppressors and metabolism bring a great interest in cancer metabolism. Tumour immune microenvironment (TIME) comprising tumour cells, immune cells, stromal cells and blood and lymph vessel cells serves as a vital role in tumour growth. Emerging evidence showed that the aberrant metabolites or intermediates of cancer metabolism are involved in the proliferation, differentiation, activation and function of immune cells. Furthermore, understanding of how specific metabolic pathways affects the TIME cells which can either suppress or promote tumour progression is necessary for immunology. In a word, cancer cells can reduce the metabolic fitness of tumor-infiltrating immune cells and thus suppress anti-tumor immune response. Considering the importance of metabolism in TIME, the restoration of the dysregulated tumor metabolic microenvironment is expected to be a target of tumor immunotherapy. For exploring the potential of cancer metabolism in the field of tumor immunology, our issue will showcase cutting-edge research and advancements between the cancer metabolism and TIME and enhance treatment outcomes.


Submission deadline: 12 April 2024

Antibiotic and Antifungal Advancements: Emerging Options and Innovative Combinations against MDR bacterial and fungal infections

Lead Editor:

    Dr Andrea Marino
    Deapartment of Clinical and Experimental medicine, University of Catania, catania, Italy
    Italy

Infections caused by multidrug-resistant (MDR) pathogens lead to higher morbidity, mortality, extended hospital stays, and increased healthcare expenses. The World Health Organization has highlighted the rise of microbes resistant to current treatments as one of the most pressing global health threats. Predictions suggest that, in the absence of effective strategies, MDR infections could claim 10 million lives annually by 2050. Infections like MDR Gram-negative Enterobacterales, MRSA, and VRE are particularly challenging in hospital environments, especially for high-risk patients in ICUs. Here, MDR bacteria and fungi can severely exacerbate an already fragile health state. Additionally, the emergence of MDR Candida spp. strains in these settings is a growing concern. Addressing the proliferation of MDR pathogens requires advanced research and new methodologies in microbiology for rapid resistance detection, improved clinical diagnostics to prevent unnecessary antimicrobial treatments, and tailored pharmacological interventions that target specific resistance mechanisms while minimizing drug exposure and side effects. This Special Issue welcomes submissions of original research, reviews, and case studies focused on novel treatment methods against MDR bacteria and fungi, emphasizing new antibiotics and drug combinations.


Submission deadline: 11 April 2024

FUNDAMENTAL AND MODERN RESEARCHES IN SEPSIS BASED ON INTERDISCIPLINARY APPROACHES

Lead Editor:

    Dr Vlad Padureanu
    University of Medicine and Pharmacy of Craiova
    Romania

Life-threatening organ malfunction brought on by an infection is known as sepsis. Considered a hidden public health disease, sepsis continues to be the greatest cause of death not just in intensive care units (ICUs) but also in all age categories globally. To improve outcomes, early diagnosis and recognition are essential. Sepsis's intricate pathophysiology leads to the release of several biomarkers. More biomarkers can be used to monitor the host's reaction to the infection, which could help clinicians treating these individuals. Since it might be challenging to distinguish sepsis from non-infectious systemic inflammatory response syndrome, one of medicine's main goals is to find a highly reliable biomarker of sepsis. Our special issue aims to provide an overview of the most current developments concerning the most often researched blood biomarkers, as assessed in clinical and experimental trials, for the purpose of early sepsis diagnosis as well as their informative value in diagnosis, prognosis, or treatment response. Since it might be challenging to distinguish sepsis from non-infectious systemic inflammatory response syndrome, one of medicine's main goals is to find a highly reliable biomarker of sepsis. Our special issue aims to provide an overview of the most current developments concerning the most often researched blood biomarkers, as assessed in clinical and experimental trials, for the purpose of early sepsis diagnosis as well as their informative value in diagnosis, prognosis, or treatment response.


Submission deadline: 10 April 2024

Deciphering the Tumor Microenvironment: Mechanistic Insights and Bioinformatics Revelations

Lead Editor:

    Dr Zhiwen Luo
    Huashan Hospital, Fudan University
    China

The tumor microenvironment (TME) plays a pivotal role in cancer progression, metastasis, and therapeutic resistance. Comprising a complex network of cellular components, extracellular matrix, soluble factors, and signaling molecules, the TME influences tumor behavior and shapes the patient's clinical trajectory. Over recent years, advancements in high-throughput technologies and bioinformatics have provided unprecedented opportunities to unravel the intricate dynamics within the TME, offering insights into mechanisms driving tumorigenesis and identifying potential therapeutic targets. By holistically deciphering the TME using both mechanistic and bioinformatics approaches, researchers can pave the way for more personalized and effective cancer therapies. This special issue seeks to showcase cutting-edge research and reviews focused on unveiling the intricacies of the TME. By diving deep into mechanistic studies and utilizing powerful bioinformatics tools, we aim to provide a comprehensive understanding of the interplay between cancer cells and their surrounding milieu, setting the stage for transformative breakthroughs in oncology. Sub-themes: 1. Cellular Components of the TME: Detailed exploration of the diverse cellular actors, such as cancer-associated fibroblasts, tumor-associated macrophages, and immune cells, and their role in shaping the tumor landscape. 2. Extracellular Matrix and Tumor Stiffness: Investigating how changes in the stiffness and composition of the extracellular matrix influence tumor progression and metastasis. 3. Mechanistic Insights into Immune Evasion: Understanding the strategies employed by tumors to evade immune surveillance within the TME. 4. Bioinformatics Analysis of TME Heterogeneity: Utilizing computational tools to delineate the heterogeneous makeup of the TME and its implications for tumor progression. 5. Metabolic Reprogramming in the TME: Exploring the metabolic shifts within the TME and their role in supporting tumor growth and survival. 6. Signaling Pathways in the TME: Elucidating key signaling pathways active within the TME, driving cancer progression, and offering potential therapeutic targets. 7. Integrative Multi-omics Analysis of the TME: Leveraging genomics, transcriptomics, proteomics, and metabolomics to provide a holistic view of the TME's dynamics. 8. Therapeutic Strategies Targeting the TME: Highlighting innovative therapeutic approaches that specifically target components of the TME, aiming to circumvent resistance and enhance treatment efficacy. With this special issue, we invite oncologists, biologists, bioinformaticians, and researchers from interdisciplinary fields to contribute their expertise, collectively illuminating the multifaceted world of the tumor microenvironment and its critical role in the cancer paradigm.


Submission deadline: 10 April 2024

Multidisciplinary treatment for hepatocellular carcinoma beyond drug therapy 

Lead Editor:

    Dr Toru Ishikawa
    Saiseikai Niigata Hospital
    Japan

Currently, drug therapy, including combined immunotherapy, is the main treatment for hepatocellular carcinoma. However, it is effective in cases classified as Child Pugh A. In actual clinical practice, this is not necessarily a Child Pugh A population. In this theme, we would like to consider multidisciplinary treatment including drug therapy.


Submission deadline: 10 April 2024

Pathogenesis and treatment advances of degenerative diseases in spine and joints.

Lead Editor:

    Dr Dasheng Lin
    Xiamen University Affiliated Southeast Hospital
    China

The spine and joints constitute important structures for human activity. With aging, as well as many factors such as obesity, labor injury, and trauma, the spine and joints undergo degenerative changes, causing symptoms such as pain and restricted movement, seriously affecting the quality of life and becoming a huge social and medical resource consumption source. For disabling diseases caused by degeneration of the spine and joints, such as lumbar disc herniation, lumbar spondylolisthesis, knee osteoarthritis, etc., the currently available treatment options are limited, and drug and highly invasive surgical treatments only address acute symptoms, lacking reliable measures to prevent or reverse the degenerative process. Due to insufficient understanding of the disease, limitations of drug and surgical treatments, and other factors, degeneration in the spine and joints remains a challenging aspect of degenerative diseases. This special issue invites researchers to focus on the latest advances in the pathogenesis and treatment of degeneration in the spine and joints, in order to address the challenges currently being faced. The following topics are welcome but not limited to: 1.Advances, basic research and clinical research related to spine and joint degeneration.; 2.Pathogenesis and treatment advances of degenerative spinal diseases, including intervertebral disc degeneration, spondylolisthesisp, degenerative scoliosis, vertebral osteoporotic fracture, etc.; 3.Pathogenesis and treatment advances of degenerative joint diseases, including osteoporosis, osteoarthritis, femoral head necrosis, ligament damage, etc.


Submission deadline: 09 April 2024

Computational RNA-mics in Personalized Medicine

Lead Editor:

    Dr Gurudeeban Selvaraj
    Concordia University
    Canada

Personalized medicine has gained increasing prominence as a transformative approach to healthcare. The ability to tailor medical treatments to an individual's unique genetic and molecular profile holds immense promise for improving patient outcomes and reducing adverse effects. One of the critical molecular players in this paradigm is RNA, which plays diverse roles in cellular processes and disease mechanisms. This special issue aims to explore the intersection of computational biology, genomics, transcriptomics, and personalized medicine, with a specific focus on RNA molecules. We invite submissions that encompass, but are not limited to, the following areas: 1. Computational Methods: Original research articles and reviews on novel computational approaches for RNA analysis, prediction, and modeling, including RNA-seq data analysis, RNA structure prediction, and RNA-protein interactions. 2. Disease Biomarkers: Research highlighting the discovery and validation of RNA-based biomarkers for disease diagnosis, prognosis, and treatment response prediction. 3. RNA Therapeutics: Contributions discussing the development and optimization of RNA-based therapies, such as RNA interference (RNAi) and mRNA vaccines, in the context of personalized medicine. 4. Precision Oncology: Studies focusing on the application of computational RNA-mics in cancer genomics, identifying actionable RNA alterations, and designing targeted therapies. 5. Single-Cell RNA Analysis: Research on single-cell RNA sequencing (scRNA-seq) and its utility in understanding cellular heterogeneity and designing individualized treatments.


Submission deadline: 07 April 2024

Journal Cover

April-2024
Volume 20 Issue 4

Print ISSN: 2049-9434
Online ISSN: 2049-9442

Sign up for eToc alerts

Recommend to Library

Full Size Image